Beta Bionics (NASDAQ:BBNX) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Beta Bionics (NASDAQ:BBNX) from a hold rating to a sell rating in a research note published on Saturday morning.

A number of other equities analysts have also issued reports on BBNX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Beta Bionics in a research report on Monday, December 29th. Piper Sandler reaffirmed an “overweight” rating and issued a $32.00 price target (up from $26.00) on shares of Beta Bionics in a research note on Wednesday, October 29th. Bank of America cut shares of Beta Bionics from a “buy” rating to a “neutral” rating in a report on Friday. Robert W. Baird set a $28.00 target price on Beta Bionics in a report on Tuesday, December 16th. Finally, Lake Street Capital upped their target price on Beta Bionics from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $30.20.

Beta Bionics Price Performance

Shares of Beta Bionics stock opened at $20.14 on Friday. The business’s fifty day moving average price is $29.28 and its two-hundred day moving average price is $22.32. The company has a market capitalization of $886.76 million and a P/E ratio of -4.61. Beta Bionics has a 1-year low of $8.89 and a 1-year high of $32.71.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings results on Tuesday, October 28th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.12. The company had revenue of $27.25 million during the quarter, compared to analysts’ expectations of $23.92 million. Beta Bionics had a negative return on equity of 35.72% and a negative net margin of 87.89%.

Insider Buying and Selling at Beta Bionics

In other news, insider Mike Mensinger sold 2,200 shares of the firm’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $30.10, for a total transaction of $66,220.00. Following the completion of the sale, the insider directly owned 80,752 shares of the company’s stock, valued at $2,430,635.20. This trade represents a 2.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Stephen Feider sold 20,000 shares of the stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $29.53, for a total value of $590,600.00. Following the completion of the transaction, the chief financial officer owned 42,614 shares of the company’s stock, valued at $1,258,391.42. This trade represents a 31.94% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 35,302 shares of company stock valued at $1,036,449.

Hedge Funds Weigh In On Beta Bionics

Several institutional investors and hedge funds have recently bought and sold shares of BBNX. SG Americas Securities LLC purchased a new stake in Beta Bionics in the 4th quarter worth approximately $4,579,000. JPMorgan Chase & Co. boosted its holdings in Beta Bionics by 3,238.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 205,955 shares of the company’s stock valued at $4,092,000 after purchasing an additional 199,785 shares during the period. Tudor Investment Corp ET AL bought a new position in Beta Bionics during the third quarter valued at about $767,000. Jacobs Levy Equity Management Inc. acquired a new position in shares of Beta Bionics in the third quarter valued at $775,000. Finally, Dark Forest Capital Management LP bought a new position in shares of Beta Bionics during the 3rd quarter worth about $1,118,000.

Key Stories Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Preliminary Q4 topline and revenue guidance: Beta Bionics announced preliminary, unaudited Q4 2025 topline growth and issued revenue guidance of roughly $32.0M versus a ~ $29.0M consensus, signaling stronger-than-expected sales momentum. GlobeNewswire – Q4 Topline Results
• Neutral Sentiment: Company release is preliminary/unaudited and EPS guidance was not specified — investors must await audited results and detailed metrics to confirm margin and profitability trends. Finanznachrichten – Preliminary Results
• Negative Sentiment: Deceleration in new patient starts: Reports highlighted a slowdown in new patient onboarding for the iLet system, which traders flagged as a demand-growth warning and a primary reason shares tumbled. Investing.com – New Patient Starts Slow
• Negative Sentiment: Analyst downgrades and valuation concerns: Multiple analysts moved to neutral/hold citing a premium valuation alongside slowing new-patient growth (Bank of America shifted to Neutral with a ~$28 PT), increasing selling pressure. DrugDeliveryBusiness – Analyst Downgrades TipRanks – Valuation & Growth
• Negative Sentiment: Insider selling: A named insider sold shares in early January (disclosed filings show several recent sales), which can weigh on sentiment when combined with downgrades and slowing customer adds. MarketBeat – Insider Trades

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.